Ignite Creation Date:
2024-05-06 @ 8:13 PM
Last Modification Date:
2024-10-26 @ 3:23 PM
Study NCT ID:
NCT06300580
Status:
RECRUITING
Last Update Posted:
2024-04-04
First Post:
2024-03-03
Brief Title:
Study of Oral ABBV-932 Capsules to Evaluate Dopamine D2 and D3 Receptor Occupancy in Brain in Adult Healthy Volunteers
Sponsor:
AbbVie
Organization:
AbbVie
Study Overview
Official Title:
An Open-Label Positron Emission Tomography PET Study to Evaluate the Dopamine D2 and D3 Receptor Occupancy in the Brain After Multiple Doses of ABBV-932
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main objective of this study is to evaluate the dopamine D2 and D3 receptor occupancy in the brain as measured by PET with radiotracer 11C--PHNO up to 14 days of once-daily oral doses of ABBV-932 in healthy subjects
ABBV-932 is a dopamine D3 receptor-preferring D3D2 receptor partial agonist Approximately 12 adult healthy volunteers will be enrolled in the United Kingdom
Participants will receive ABBV-932 oral capsules once daily for 2 weeks and followed for 60 days
Participants will be confined for approximately 15 days Participants will receive 3 11C--PHNO PET scans during the study Adverse Events and blood tests will be performed
ABBV-932 is a dopamine D3 receptor-preferring D3D2 receptor partial agonist Approximately 12 adult healthy volunteers will be enrolled in the United Kingdom
Participants will receive ABBV-932 oral capsules once daily for 2 weeks and followed for 60 days
Participants will be confined for approximately 15 days Participants will receive 3 11C--PHNO PET scans during the study Adverse Events and blood tests will be performed
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None